McDermott Will & Emery Joins RESI NYC As a Title Sponsor

By Natasha Eldridge, Director of RESI Conference Series, LSN

natasha-wp-new

Life Science Nation (LSN) is proud to announce that McDermott Will & Emery will serve as a title sponsor for the inaugural RESI NYC on November 15, 2017.  McDermott joins RESI NYC title sponsors WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, and Johnson and Johnson Innovation (JLABS), which provides state of the art laboratories, core research facilities, resources and connections to early stage life science innovators.

“We are proud to have been a sponsor of RESI since its inception and are particularly excited to join Wuxi AppTec and JLABS as title sponsors of the inaugural RESI in New York, a burgeoning region for life sciences,” said Byron Kalogerou, founder and chair of the firm’s Life Sciences Industry Group.  “We are continually impressed at the global convening power of RESI in its ability to connect early stage CEOs with the full spectrum of funding sources from VCs, corporate VCs, family offices and sovereign funds to venture philanthropies.  We are excited that many of our early stage clients in our Life Sciences Entrepreneurs Acceleration Program (“LEAP”) will have an opportunity to participate as well.”

“We look forward to sharing our legal insights with RESI attendees in New York in November, and at the September conference in Boston, where we will convene a panel on negotiating term sheets to be led by McDermott Will & Emery attorneys Brian Bunn and Jonathan Ursprung,” said Kalogerou.  “Our new partner, Linda Ji, will moderate the RESI panel on Chinese Investment.”

McDermott Will & Emery offers deep experience in health care and life sciences, and provides a continuum of legal services that will meet the needs of life sciences companies at every stage of development.  The firm’s Life Sciences Industry Group is comprised of 135 professionals, 60 with advanced degrees and many others with government and industry experience across 19 offices around the world.  Learn more here.

 

New at RESI Boston and RESI NYC: Academic and Tech Transfer Registration

By Lauren Schulkamp, Business Development Manager-RESI Conference Series, LSN

lauren-wp

We are excited to welcome academic scientists and tech transfer professionals to RESI for the first time.  The Redefining Early Stage Investments Conference (RESI) is now offering a special academic rate to universities, institutes, tech transfer offices, and hospitals to shine the spotlight on some of the most innovative emerging technology.  If you’d like to come to RESI to network with over 300 early stage life science investors, you can get an academic registration online now.  Academic registration includes the following:

  • All day access pass to 24 panels & workshops, RESI’s ad hoc meeting area, Exhibit Hall and Innovation Challenge, meals, and the evening Cocktail Reception
  • Full day of networking with early stage investors and pharma external innovation staff
  • Learn from life science investors and understand their investment strategies
  • Listen to current fundraising life science CEOs describe their process in developing a fundraising strategy
  • Get to know the experts as they explain the valuation process, organizing an outbound marketing campaign, negotiating term sheets, and other post-academia commercialization topics

Click here for a complete list of RESI Boston Panels & Workshops

** RESI Partnering is not included in the academic and tech transfer registration

To qualify you must:

  • Be affiliated with a non-profit certified 501(c)(3) organization. This includes universities, institutes, tech transfer offices, and hospitals
  • Register with an email address corresponding with the organization you are representing
  • Provide proof of current position – this can be done by sending proof via email to resi@lifesciencenation.com

Payers and Providers as Value Adding Health Tech Investors

By Michael Quigley, VP of Investor Research, LSN

mike-2

Healthcare payers and healthcare providers alike stand to gain significant increases in cost efficiency as a result of the successful implementation of new technologies into their workflows and into the lives of the patients they care for and insure. As such it is no surprise that many of these groups have begun investing into early stage technologies, either through their own corporate venture vehicles or by sponsoring external venture funds.

Beyond simply providing capital, these groups represent a tremendous value-adding resource for the companies that they invest in.  Based on our conversations and experience in reaching out to these groups on behalf of companies, they are almost exclusively investing with a strategic mandate, targeting technologies where they can be a customer or help drive adoption in a meaningful way. This leads to them primarily focusing on healthcare IT, tech-enabled services and, to a lesser extent, low-risk medical technologies.

An interesting parallel can be drawn between these payer and provider linked funds in the digital health space and large pharma groups for therapeutics. Both bring significant expertise to the table in their respective sector and invaluable development advice; lower the risk of customer acquisition (for healthcare IT companies) or M+A/exit risk for therapeutics if the technologies do work and they provide a significant level of validation in the technology for other investors looking to co-invest or participate in later rounds. To put it simply, if I was a digital health entrepreneur, these kinds of funds would be at the top of my list when fundraising.

At RESI Boston on Sept 26th, the Payer & Provider Venture Funds Panel will feature 4 speakers from these funds, who will discuss the types and stages of technologies they are looking for, how they add value outside of capital, and where they see their space going in the next few years. Attendees of the session will hear from:

If you’d like to hear the advice of these investors, you can register for RESI now.

Big Data in Drug Discovery: 5 Experts Share Their Thoughts at RESI Boston

By Michael Quigley, VP of Investor Research, LSN

mike-2To reduce the massive costs associated with getting a new drug approved, many startups, large pharma companies, venture funds, and others are looking to big data for a solution. These firms are researching, partnering, and investing into machine learning and artificial intelligence systems that scour through massive drug and target libraries to more quickly identify potential candidates than a team of researchers could. These technologies are leveraging all kinds of scientific and medical data including chemical, biologic, genomic and clinical datasets to best identify candidates. Companies are touting their tech promises “years” of savings and lower failure rates in research that can now be done through advanced algorithms. This may seem like quite the promise, but if you look at the number and size of deals in the space just in the past year, it’s clear that big players are listening (1, 2, 3, 4, 5, 6).

At RESI Boston this September 26th we are bringing together a panel of 5 experts in this space to discuss their thoughts on the challenges and opportunities that the use of Big Data in Drug Discovery currently faces. These speakers include a promising company with an emerging drug discovery technology, a massive CRO, and three venture funds, all actively working in this space. Look below to see the speakers for yourself. This is another cutting-edge session you won’t want to miss!

  • Richard Soll, Senior Vice President, Research Service Division, WuXi AppTec (moderator)
  • Gini Deshpande, Founder and Chief Executive Officer, NuMedii, Inc.
  • Millie Liu, Founding Partner, Managing Director, Procyon Ventures
  • Dylan Morris, Partner, CRV
  • Annie Hazlehurst, Founder, Faridan
  1. http://www.fiercebiotech.com/medtech/gsk-taps-baltimore-s-insilico-for-ai-based-drug-discovery
  2. https://www.reuters.com/article/us-astrazeneca-ai-berg/astrazeneca-taps-ai-for-drug-discovery-in-deal-with-berg-idUSKCN1B81G1
  3. http://www.koreabiomed.com/news/articleView.html?idxno=1254
  4. http://www.prnewswire.com/news-releases/wuxi-nextcode-ai-points-to-new-therapeutic-approaches-to-cardiovascular-disease-and-cancer-in-yale-nature-study-300457412.html
  5. http://www.wired.co.uk/article/benevolent-ai-london-unicorn-pharma-startup
  6. http://www.prnewswire.com/news-releases/numedii-inc-announces-new-partnership-to-discover-and-advance-new-treatments-for-idiopathic-pulmonary-fibrosis-300437651.html

How to Get the Most Out of Life Science Partnering Events

By Lucy Parkinson, Director of Research, LSN

RESI Boston is approaching, and partnering requests are flying back and forth between attendees. As this is the 14th RESI event, LSN has gathered a great deal of information and insight on the partnering process. We’ve seen how skilled entrepreneurs take steps to increase their partnering success. Based on our observations, here are a few keys to partnering success:

Numbers Are Key

A simple truth underlies a lot of our other insights: Entrepreneurs that send more requests get more meetings. However, those requests have to be directed at relevant investors. The below chart plots the relationship between the number of requests sent via RESI Partnering and the number of meetings booked. This makes it clear that your goal is to surface as many relevant investors at the partnering event as possible and provide them with a clear reason to meet with you.

Make A Target List

Many partnering events claim a high number of investor attendees, but what’s important is to find out which of those investors are potentially relevant for your opportunity. The RESI website includes a list of investors that are signed up to attend, and LSN’s Research team speaks to all those investors prior to the event in order to understand their investment interests and criteria. RESI attendees can therefore search RESI Partnering to get a complete view of the most relevant attending investors. At other events, the partnering system may not provide this information as consistently — you may need to do your homework on the attending investors. A search online for their portfolios and stated interests should reveal which are most relevant for you.

Log In Early and Often

As a partnering event approaches, investors will find many meeting requests in their system inbox. Some investors like to look at those requests as soon as they come in, and may fill up their schedule with interesting startups quite early. However, it’s more common for investors to select their meetings close to the event — and some investors only sign up for events at the last minute. There’s therefore an advantage to getting a set of requests out as soon as the system opens to catch the earlybirds; however, running regular searches to look for new attendees as the event approaches will allow you to identify new targets and increase your meeting count.

Don’t Limit Your Investor Universe

At RESI, we welcome a broad variety of investors, including venture capital firms, big pharma, family offices, venture philanthropy funds, angels, and many more. Any of these investors could potentially be a fit for your round. As we covered in last week’s Next Phase, some entrepreneurs make the mistake of focusing only on the top 25 big name VC funds. If one of these funds has an investment staff member at the event, it’s definitely worth shooting them an invite, but if you only send requests to attendees from these firms, you’re likely to lose a large part of the value of the event. Partnering events are a great opportunity to broaden your network; the most relevant firms represented at the event might be those you’ve never heard of or those who you hadn’t previously considered approaching for investment. Equally, don’t dismiss a firm because they’re based far from your headquarters; many international investors attend partnering events specifically because they want to broaden their exposure to overseas deal flow.

Write A Clear Intro Message and Profile

You’d be surprised how many CEOs send partnering requests with only a one-sentence message, or no message at all. Similarly, many may neglect to fill out their profiles, or forget to update their pre-loaded profiles from last year’s event. It’s important to keep in mind that the investor will have received a deluge of meeting requests, and if you don’t make your company’s relevance immediately clear, they will move on to the next request. Make sure that your message clearly describes what your company does and why it’s aligned with that particular investor’s interests, and be sure that if they click through to your profile they’ll have access to all the vital information needed to determine that you are a fit for their firm.

Follow Up On Your Requests

To maximize your partnering success, you should reach beyond the partnering system. For each investor on your target list at the event, try to find further contact info. Send an email or make a quick call to tell them what your company does and why you’re highly interested in meeting with them at the event. With so many messages to go through, an extra nudge may be necessary to direct the investor’s attention to your company. For RESI Boston, we’ve therefore created the new RESI Premier Partnering Plus Registration which provides investor contact info in order to help entrepreneurs follow up on their meeting requests.

RESI is approaching on September 26th – if you would like to put this advice to work and start filling out your meeting schedule, register now.

Diagnostic Investors Explore Their Strategies at RESI Boston

By Lucy Parkinson, Director of Research, LSN

Personalized medicine, NGS and new biomarkers promise a new age of tailored, targeted medical care. However, diagnostics is a notoriously challenging landscape for both entrepreneurs and investors. Through our research and outreach, LSN has found that many investors are still looking at diagnostic opportunities, with some focusing exclusively or primarily on the sector. At RESI Boston, we’ve gathered five experienced investors from both the venture and corporate worlds to explain what they’re looking for in the sector and how entrepreneurs can improve their odds of finding funding for their diagnostic business.

Moderated by Tom Miller, Managing Director, GreyBird Ventures, the panelists are:

  • Alex Dewinter, Director, GE Ventures
  • Wouter Meuleman, (Director of Investments, Illumina Ventures
  • Diana Saraceni, Founder & Managing Director, Panakes Partners
  • Adam Lessler, Vice President, Canepa Healthcare

In addition to these five experts, nearly a hundred investors attending RESI have an interest in diagnostic opportunities. If you’re looking for investment in this sector, sign up now.

Next Phase Interview: NCI Program Director Todd Haim Explains How RESI Boston Became A Showcase For NIH SBIR Grantees

For the third year in a row, the NIH has sponsored a group of grantees to be part of the RESI Boston Innovation Challenge. This week, Dennis Ford(DF) interviews Program Director Todd Haim(TH) to explore how this relationship benefits the NIH’s grantees, and how RESI stands out as a venue for these companies to present.

Dennis Ford
Founder & CEO, Life Science Nation; Creator of RESI Conference Series
Todd Haim
SBIR Program Director, National Cancer Institute

 

 

 

 

 

 

DF: What is the basic reason NIH is showcasing technology at RESI?

TH: The NIH is supporting the SBIR awardees to showcase their own technologies, and we do this at a variety of industry conferences. And the real goal from the NIH´s perspective is that we realize that we cannot support these companies forever; and that each individual company, in order to reach the patient and the market, will need a lot more funding than can be provided just through SBIR. They will need downstream partners and funders, and it is in our interest to help as much as we can to facilitate those partnerships.  RESI along with other early stage investor conferences provides a forum for our portfolio companies to interact with these parties. The conference hosts a unique set of investors and partners that are a good match for our Investor Initiatives program. This is the third year that we will be sending our companies to RESI.

DF: How many NIH-funded companies apply for the RESI Innovation Challenge and how many are selected as finalists?

TH: Over the past 3 years, over 150 companies have applied, and 60 of those have been featured as finalists. 20 at each conference.

DF: What are some key differences you see in the RESI conference compared to other conferences you attend?

TH: I would say two things stand out about RESI. One is the inclusion of Family Offices and groups that you don´t see at many other industry forums and showcases. The other benefit of RESI is the broad base in terms of technology types. Many of the other conferences we have participated in are really focused on one technology area, whether it be devices or therapeutics. RESI has individual tracks that represent devices or that represent therapeutics, which really allows us to present a greater variety of our companies there, and I think that broad focus is very helpful at this early stage.

DF: Is this type of showcasing of NIH-funded technology going to continue?

TH: We continually evaluate the outcomes of our companies’ participation in conferences like RESI to ensure the value of such events to our portfolio companies. We recently found out that CellSight Technologies, one of the companies that attended RESI as part of NCI SBIR’s Investor Initiatives, signed an agreement with Boehringer Ingelheim to partner on a clinical study using CellSight’s technology. We hope that participation in NCI SBIR’s Investor Initiatives will result in additional partnerships and investment for our portfolio companies. Should RESI participation continue to prove effective for NCI SBIR’s portfolio companies and our program continue to have sufficient funding for these efforts, we are likely to continue considering participation in RESI.

DF: Typically, we see for the Innovation Challenge participants up to 50% get funded or get involved in partnerships but we haven’t correlated that to SBIR participants specifically (though I know of around a half dozen off the top of my head that have fared quite well by participating in RESI). 

DF: Tell the readers some great stuff that is happening right now in the NIH funding domain:

TH: Sure. NCI and many of the other Institutes participate in both the Omnibus grant funding opportunity, which is available three times a year and the next receipt date is September 5th. About two thirds, if not more, of the funding for the NIH/SBIR program is actually through the Omnibus solicitation, which is an investigator initiated solicitation. You submit the application and you tell us what you’re working on; then it gets peer reviewed and we consider it from there. Then we have some of the Institutes within the Health and Human Services (HHS) including NCI, using a SBIR Contract Solicitation that goes out once a year to fund high-priority areas for each of those Institutes. The solicitation is now available and applications are due by October 20th. You can find the solicitation on NCI SBIR’s website (https://sbir.cancer.gov), as well as on https://sbir.nih.gov. I would definitely encourage all of the readers to look at both of those funding opportunity announcements with upcoming due dates and consider applying. We are here to work with potential applicants and help them understand how the program works, and how an application can be competitive.  So I encourage you to reach out to our office (ncisbir@mail.nih.gov) or to the SBIR Program Officers and Coordinators across the NIH before you apply. If you would like to speak to a Program Officer before you apply, that is definitely something we can arrange and provide guidance. Come and talk to us, we’re always interested in supporting new companies through the SBIR program and new projects.